Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Paradigm Biopharmaceuticals ( (AU:PAR) ) is now available.
Paradigm Biopharmaceuticals has activated its first clinical sites in the United States for a phase 3 study on knee osteoarthritis, marking a significant milestone in its global clinical development strategy. The study aims to evaluate the effectiveness of iPPS in treating moderate-to-severe knee osteoarthritis, with patient recruitment and site activation progressing in both the US and Australia, potentially accelerating the company’s market presence and offering new treatment options for patients.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Ltd. is a late-stage drug development company focused on improving patients’ health and quality of life by developing pharmaceutical therapies. The company is currently concentrating on developing injectable pentosan polysulfate sodium (iPPS) for treating diseases where inflammation is a major factor, such as osteoarthritis and mucopolysaccharidosis.
YTD Price Performance: -14.67%
Average Trading Volume: 872,229
Technical Sentiment Signal: Sell
Current Market Cap: A$124.6M
See more data about PAR stock on TipRanks’ Stock Analysis page.